KOSDAQ - Delayed Quote KRW

Sam Chun Dang Pharm. Co., Ltd (000250.KQ)

104,600.00 -3,900.00 (-3.59%)
At close: 3:18 PM GMT+9
Currency in KRW All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
192,668,515.62
192,668,515.62
177,335,410.01
167,274,903.87
166,862,333.79
Cost of Revenue
95,702,222.19
95,702,222.19
87,340,758.05
84,196,690.19
72,862,414.44
Gross Profit
96,966,293.43
96,966,293.43
89,994,651.96
83,078,213.68
93,999,919.35
Operating Expense
87,406,478.00
87,406,478.00
77,770,000.00
98,371,301.00
88,477,014.00
Operating Income
9,559,815.43
9,559,815.43
12,224,651.96
-15,293,087.32
5,522,905.35
Net Non Operating Interest Income Expense
210,992.22
210,992.22
-672,681.15
-461,230.60
992,584.43
Pretax Income
-4,548,519.77
-4,548,519.77
8,919,524.09
-19,549,099.49
16,580,831.05
Tax Provision
-360,766.22
-360,766.22
87,703.62
-9,188,213.04
9,085,845.10
Net Income Common Stockholders
-10,382,721.09
-10,382,721.09
5,837,527.76
-16,555,159.16
-965,677.31
Basic EPS
-463.00
--
265.00
-750.00
-45.00
Diluted EPS
-463.00
--
265.00
-750.00
-45.00
Basic Average Shares
22,424.88
--
22,028.41
22,073.55
21,459.50
Diluted Average Shares
22,688.53
--
--
22,073.55
21,459.50
Total Operating Income as Reported
9,559,814.33
9,559,814.33
12,224,651.49
-15,293,087.30
5,522,905.19
Rent Expense Supplemental
88,714.00
88,714.00
58,051.00
56,860.00
61,518.00
Total Expenses
183,108,700.19
183,108,700.19
165,110,758.05
182,567,991.19
161,339,428.44
Net Income from Continuing & Discontinued Operation
-10,382,721.09
-10,382,721.09
5,837,527.76
-16,555,159.16
-965,677.31
Normalized Income
2,670,486.36
2,670,486.36
9,482,241.25
-13,318,069.91
-10,223,631.56
Interest Income
2,788,057.00
2,788,057.00
2,120,621.00
1,435,326.00
1,630,997.00
Interest Expense
2,577,066.00
2,577,066.00
2,793,303.00
1,896,557.00
638,413.00
Net Interest Income
210,992.22
210,992.22
-672,681.15
-461,230.60
992,584.43
EBIT
-1,971,453.77
-1,971,453.77
11,712,827.09
-17,652,542.49
17,219,244.05
EBITDA
6,458,980.05
6,458,980.05
19,363,697.73
-10,911,988.70
23,904,574.85
Reconciled Cost of Revenue
95,702,222.19
95,702,222.19
87,340,758.05
84,196,690.19
72,862,414.44
Reconciled Depreciation
8,430,433.82
8,430,433.82
7,650,870.64
6,740,553.79
6,685,330.80
Net Income from Continuing Operation Net Minority Interest
-10,382,721.09
-10,382,721.09
5,837,527.76
-16,555,159.16
-965,677.31
Total Unusual Items Excluding Goodwill
-14,177,714.00
-14,177,714.00
-3,680,907.00
-4,316,119.00
12,343,939.00
Total Unusual Items
-14,177,714.00
-14,177,714.00
-3,680,907.00
-4,316,119.00
12,343,939.00
Normalized EBITDA
20,636,694.05
20,636,694.05
23,044,604.73
-6,595,869.70
11,560,635.85
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-1,124,506.55
-1,124,506.55
-36,193.51
-1,079,029.75
3,085,984.75
12/31/2020 - 9/11/2001

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade